Viestar
A new type of endoscopic microscopic imaging system, which adopts advanced biological cytology analysis technology principle, combined with exquisite optical system and unique algorithm processing, realizes ultra-high resolution capability and ultra-small observation end size.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
* | CNY20.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Biopsee.cn specializes in ultra high resolution in vivo microscopic imaging, providing advanced diagnostic solutions for the medical industry. The company serves healthcare providers, research institutions, and clinical laboratories, operating primarily in the medical imaging market. Biopsee.cn's business model revolves around the development and sale of cutting-edge imaging technology, which enables precise and detailed visualization of biological tissues in real-time. Revenue is generated through the sale of imaging devices, maintenance services, and software solutions that enhance diagnostic capabilities. The company aims to improve clinical outcomes by offering superior imaging quality that aids in early and accurate diagnosis.
Keywords: ultra high resolution, in vivo imaging, microscopic imaging, clinical diagnostics, medical technology, healthcare providers, research institutions, imaging devices, diagnostic solutions, medical imaging market.